Progenity Supports the Preeclampsia Foundation Call to Action to Accelerate Development and Adoption of Biomarker Tests for Preeclampsia

By adminOctober 17, 2020Global News Feed

SAN DIEGO, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced support for the Preeclampsia Foundation’s recent call to action advocating for accelerating the development and clinical adoption of biomarker tests for the diagnosis of preeclampsia, a life-threatening hypertensive disorder of pregnancy. The foundation issued its call to action urging the life science community and policy makers to accelerate the development and adoption of biomarker-based testing for preeclampsia.

View post:
Progenity Supports the Preeclampsia Foundation Call to Action to Accelerate Development and Adoption of Biomarker Tests for Preeclampsia

Auxly Strengthens its Board and Announces Additional Steps on Path to Profitability

By adminOctober 17, 2020Global News Feed

TORONTO, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V - XLY) ("Auxly" or the “Company”) today announces changes to its Board of Directors and management team and a Company-wide operational update on its path to profitability.

Read the original:
Auxly Strengthens its Board and Announces Additional Steps on Path to Profitability

OliX Pharmaceuticals to Present New Data in Liver and Ophthalmic Areas at 16th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)

By adminOctober 17, 2020Global News Feed

SUWON, Republic of Korea, Sept. 29, 2020 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, presents two virtual posters of their on-going clinical research at the 16th Annual Meeting of the Oligonucleotide Therapeutics Society on September 27 – 30. The presentations will focus on the results of the Company’s proprietary asymmetric siRNA (asiRNA) study, which confirms the therapeutic effects of RNAi-based therapeutics in patients with hepatic diseases and age-related macular degeneration.

Read the original post:
OliX Pharmaceuticals to Present New Data in Liver and Ophthalmic Areas at 16th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)

Capital Increase in Genmab as a Result of Employee Warrant Exercise

By adminOctober 17, 2020Global News Feed

Company Announcement

Read more here:
Capital Increase in Genmab as a Result of Employee Warrant Exercise

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

By adminOctober 17, 2020Global News Feed

Company Announcement

Link:
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Cytovia Therapeutics to present at Jefferies Cell Therapy Virtual Summit, BIO Investor Forum and New York Stem Cell Foundation Conference in October…

By adminOctober 17, 2020Global News Feed

NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, an emerging biopharmaceutical company developing Natural Killer Cell Therapeutics, today announced that it will participate in three key conferences in October 2020.

See more here:
Cytovia Therapeutics to present at Jefferies Cell Therapy Virtual Summit, BIO Investor Forum and New York Stem Cell Foundation Conference in October...

Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trial

By adminOctober 17, 2020Global News Feed

Mechelen, Belgium; 29 September 2020, 22.01 CET – Galapagos NV (Euronext & NASDAQ: GLPG) announces dosing of a first patient in their psoriasis trial, one of three patient trials currently recruiting to evaluate efficacy and safety of Toledo compound GLPG3970. Furthermore, Galapagos plans to unveil the novel Toledo target class and share GLPG3970 Phase 1 data at its inaugural Toledo Roundtable to be held virtually on 27 October 2020.

Original post:
Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trial

Rubius Therapeutics to Participate in 7th Annual Jefferies Cell Therapy Summit

By adminOctober 17, 2020Global News Feed

CAMBRIDGE, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that Laurence Turka, M.D., chief scientific officer, will participate in a fireside chat at the 7th Annual Jefferies Cell Therapy Summit on Monday, October 5, 2020, at 4:00 p.m. ET.

View post:
Rubius Therapeutics to Participate in 7th Annual Jefferies Cell Therapy Summit

PMV Pharma Announces Closing of $243.5 Million Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

By adminOctober 17, 2020Global News Feed

CRANBURY, N.J., Sept. 29, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, today announced the closing of its initial public offering of 13,529,750 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 1,764,750 additional shares of common stock, at a public offering price of $18.00 per share. The aggregate gross proceeds to PMV Pharma from the offering were approximately $243.5 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by PMV Pharma. PMV Pharma’s common stock is listed on the Nasdaq Global Select Market under the ticker symbol “PMVP.”

Read the original:
PMV Pharma Announces Closing of $243.5 Million Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

Translate Bio to Participate in Upcoming Investor Conferences

By adminOctober 17, 2020Global News Feed

LEXINGTON, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today announced that the Company will participate in the following upcoming investor conferences:

Read the original here:
Translate Bio to Participate in Upcoming Investor Conferences